BioRankings, LLC
BioRankings LLC is a biostatistical consulting service providing statistical due diligence to identify strengths and weaknesses of statistical data that may impact a biotech firm’s long term viability. Founded by Dr. William Shannon, Associate Professor of Biostatistics in Medicine at the Washington University School of Medicine in St. Louis, BioRankings LLC brings over 20 years of applied biostatistical expertise in biomedical, pharmaceutical, and biotech research. In addition to over 80 peer-reviewed publications in diverse areas such as oncology, pediatrics, genetics, cardiology, pulmonology, infectious disease, sleep medicine, health care delivery, and many other areas, BioRankings LLC staff have advanced technical expertise in biotechnology, genetics, cell and molecular biology, and technical writing. Our combined expertise allows us to make complex biostatistical ideas understandable.
Area of focus:
Biostatistics, Experimental Design, Independent Statistical Analysis, Phase I/II/III Clinical Trials, Statistical Due Diligence
Leading Experts at BioRankings, LLC(?)
Total Experts: 1
-
Founder and President
William Shannon, PhD, is an Associate Professor of Biostatistics at Washington University School of Medicine, since 1995; and Founder and President of BioRankings, a pharma IT firm, since January 2007. Dr. Shannon has over 20 years of applied biostatistical expertise in biomedical, pharmaceutical,and...
GLG NewsSMAnalyses by Leading Experts at BioRankings, LLC(?)
Analyses are solely the work of the authors and have not been edited or endorsed by GLG.
Top 5 Recent News
-
Meta-analysis of probiotics in atopic dermatitis
April 16, 2009
William Shannon, PhD, Founder and President, BioRankings, LLC
Probiotics for the treatment or prevention of atopic dermatitis: a review of the evidence from randomized controlled trials. | www.ncbi.nlm.nih.gov
The use of meta-analysis to evaluate probiotics in this condition is commendable. The abstract suggests that improvement may be real, but the evidence presented indicates that probiotics may be ineffective on careful reading. The abstract is lacking information needed to determine the quality of the meta-analysis and whether its results/suggestions should be considered in investment decisions....
-
New FDA effort takes aim at genomics: Inherent risk to investors
February 6, 2009
William Shannon, PhD, Founder and President, BioRankings, LLC
New FDA Effort to Take Aim at Genomics | www.genomeweb.com
The risk to an investor in genomic or personalized medicine is significant and a clear understanding of the low power and high risk of false-positives needs to be kept in mind. The establishment at the FDA of a senior scientist to oversee and coordinate genomic activities is necessary but not necessarily sufficient to insure that future genomic treatments are effective.
-
Eli Lilly's Personal Medicine Goal
November 27, 2008
William Shannon, PhD, Founder and President, BioRankings, LLC
Personal medicine is goal of Eli Lilly & Co. | www.azcentral.com
The Chairman of Eli Lilly announcing that personalized medicine (e.g., pharmacogenetics) is a major shift in strategy for big pharma could impact in a significant way the market share for new drugs and the amount of money for research needed to bring a targeted therapy to market. If this strategy is widely accepted the likely impact on small biotech firms will be a significant increase in their value...
-
Dealing with publication bias using the 'file drawer' scenario.
October 28, 2008
William Shannon, PhD, Founder and President, BioRankings, LLC
Many Trial Reports on FDA-Approved Drugs Go Unpublished | www.washingtonpost.com
In this meta-analysis, the authors looked at the number of studies, if any, per new drug application with the FDA that got published, at what time, and how much information they released. They concluded that there is strong evidence of publication bias in what the drug companies will make public, with only 76% of pivotal trials and 24% of non-pivotal trials making publication. We looked at how this...
-
Is Biodel's argument to drop the India data from analysis valid?
October 9, 2008
William Shannon, PhD, Founder and President, BioRankings, LLC
Biodel Releases Preliminary Phase III Clinical Trials for VIAject | www.fiercebiotech.com
Biodel’s September 8th announcement of the Phase III non-inferiority trial results for VIAject at the 44th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Rome left many investors wary of the legitimacy of the data that was presented. The study, which was originally conducted in the US, Germany, and India, did not include the data from the Type 1 study in India in its...
View All GLG News Analyses by Leading Experts at BioRankings, LLC
GLG Study Groups Relevent to Leading Experts at BioRankings, LLC(?)
| Study Group Name | No. Members |
|---|---|
| Biostatisticians | 381 |
| Biostatisticians (US) | 254 |
GLG Live Meetings Hosted by Leading Experts at BioRankings, LLC
Leading Experts at BioRankings, LLC are not hosting any Live Meetings